微创CentriMag心室辅助装置联合ECMO与常规双心室辅助在心源性休克中的比较
本研究对比了微创CentriMag心室辅助装置联合体外膜氧合(Ec-VAD)与常规正中开胸CentriMag双心室辅助装置(BiVAD)在心源性休克患者中的 outcomes。2015年7月至2016年8月,22例接受Ec-VAD,90例接受常规BiVAD。
要点
- Ec-VAD组大出血事件显著低于BiVAD组(32% vs 72%,P<0.01)。
- Ec-VAD组术中无需体外循环(0% vs 66%,P<0.01)且输血需求更少。
核心结论
- Ec-VAD是治疗心源性休克的一种独特方法,可避免体外循环并减少血制品使用和出血事件。
研究设计与样本
- 回顾性比较研究,2015年7月至2016年8月纳入22例接受CentriMag Ec-VAD的患者和90例接受常规CentriMag BiVAD的患者。
主要发现
- Ec-VAD组患者年龄更大(58 ± 9.9 vs 53 ± 13岁,P = 0.06),术前经皮机械循环支持使用更多(82% vs 44%,P < 0.01),术中体外循环使用更少(0% vs 66%,P < 0.01)。
- Ec-VAD组输血需求更少,支持期间大出血事件发生率显著更低(32% vs 72%,P < 0.01)。
- 平均系统流量相似(Ec-VAD:5.5 ± 0.94 vs BiVAD:5.7 ± 1.1 l/min,P = 0.4)。
临床怎么用
- 对于心源性休克需短期循环支持的患者,Ec-VAD可作为一种避免体外循环、减少输血和出血事件的微创选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We recently developed a novel minimally invasive surgical approach that combines extracorporeal membrane oxygenation and CentriMag ventricular assist device (Ec-VAD) for the treatment of cardiogenic shock as a short-term circulatory support. We compared the outcomes of this new approach to conventional CentriMag biventricular assist device (BiVAD) support through a median sternotomy. METHODS: Between July 2015 and August 2016, 22 patients were implanted with CentriMag Ec-VAD and 90 patients were implanted with conventional CentriMag BiVAD. The Ec-VAD circuit was configured with left ventricular apical cannulation via a mini-thoracotomy and femoral venous cannulation as inflows and right axillary artery cannulation as an outflow. RESULTS: Patients with Ec-VAD were older (58 ± 9.9 vs 53 ± 13 years, P = 0.06), had more preoperative percutaneous mechanical circulatory support use (82% vs 44%, P < 0.01) and less cardiopulmonary bypass use intraoperatively (0% vs 66%, P < 0.01). Patients who received Ec-VAD required less transfusions. The Ec-VAD group had a significantly lower incidence of major bleeding events during support (32% vs 72%, P < 0.01). Average systemic flow was similar (Ec-VAD: 5.5 ± 0.94 vs BiVAD: 5.7 ± 1.1 l/min, P = 0.4). Seventeen patients (77%) with Ec-VAD survived to the next destination compared with 66 patients (73%) with BiVAD (P = 0.45). Thirty-day survival was similar between groups (Ec-VAD 86% vs BiVAD 76%, P = 0.39), and overall 1-year survival was 61% in Ec-VAD and 55% in BiVAD (P = 0.7). CONCLUSIONS: Ec-VAD is a unique approach for the treatment of patients in cardiogenic shock. It eliminates the need for cardiopulmonary bypass and reduces blood product utilization and bleeding events.
引用
- Takeda K, Garan AR, Ando M, et al. Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients: a comparison with conventional CentriMag biventricular support configuration. Eur J Cardiothorac Surg. 2017. PMID: 28651347. doi:10.1093/ejcts/ezx189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。